Evidence map›Paper›PMID 38866770›Full record

ArticleNature communications2024

UBE2D3 facilitates NHEJ by orchestrating ATM signalling through multi-level control of RNF168.

Zeliha Yalçin, Shiu Yeung Lam, Marieke H Peuscher, Jaco van der Torre, Sha Zhu, Prasanna V Iyengar, Daniel Salas-Lloret, Inge de Krijger, Nathalie Moatti, Ruben van der Lugt and 6 more

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Ubiquitin-conjugating Enzymes in Cancer.International journal of biological sciences · 2026
    Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Zeliha Yalçin *Division of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0001-9780-0140
Shiu Yeung Lam *Division of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0003-3001-3112
Marieke H PeuscherDivision of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands.
Jaco van der TorreDivision of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0002-5405-3824
Sha ZhuDivision of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands.
Prasanna V IyengarDivision of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands.
Daniel Salas-LloretDepartment of Cell and Chemical Biology, Leiden University Medical Center, Einthovenweg 20, 2333 ZC, Leiden, the Netherlands.ORCID http://orcid.org/0000-0001-7336-2887
Inge de KrijgerDivision of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands.
Nathalie MoattiDivision of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands.
Ruben van der LugtDivision of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands.
Mattia FalconeDivision of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0003-0906-5735
Aurora CeruttiDivision of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands.
Onno B BleijerveldProteomics Facility, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0002-9395-2347
Liesbeth HoekmanProteomics Facility, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0002-3552-6390
Román González-PrietoDepartment of Cell and Chemical Biology, Leiden University Medical Center, Einthovenweg 20, 2333 ZC, Leiden, the Netherlands.ORCID http://orcid.org/0000-0001-8997-2321
Jacqueline J L JacobsDivision of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands. j.jacobs@nki.nl.ORCID http://orcid.org/0000-0002-7704-4795

Funding

EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 Marie Skłodowska-Curie Actions (H2020 Excellent Science - Marie Skłodowska-Curie Actions) H2020-MSCA-ITN-2018: 812829KWF Kankerbestrijding (Dutch Cancer Society) institutional grantKWF Kankerbestrijding (Dutch Cancer Society) KWF 12826/2019-2KWF Kankerbestrijding (Dutch Cancer Society) KWF-NKI 2007-3907KWF Kankerbestrijding (Dutch Cancer Society) KWF-NKI 2012-5305KWF Kankerbestrijding (Dutch Cancer Society) KWF-YIG 11367Ministerie van Volksgezondheid, Welzijn en Sport (Dutch Ministry of Health, Welfare and Sport) institutional grantNederlandse Organisatie voor Wetenschappelijk Onderzoek (Netherlands Organisation for Scientific Research) Netherlands X-omics Initiative
6 · The paper itself

Abstract

Maintenance of genome integrity requires tight control of DNA damage response (DDR) signalling and repair, with phosphorylation and ubiquitination representing key elements. How these events are coordinated to achieve productive DNA repair remains elusive. Here we identify the ubiquitin-conjugating enzyme UBE2D3 as a regulator of ATM kinase-induced DDR that promotes non-homologous end-joining (NHEJ) at telomeres. UBE2D3 contributes to DDR-induced chromatin ubiquitination and recruitment of the NHEJ-promoting factor 53BP1, both mediated by RNF168 upon ATM activation. Additionally, UBE2D3 promotes NHEJ by limiting RNF168 accumulation and facilitating ATM-mediated phosphorylation of KAP1-S824. Mechanistically, defective KAP1-S824 phosphorylation and telomeric NHEJ upon UBE2D3-deficiency are linked to RNF168 hyperaccumulation and aberrant PP2A phosphatase activity. Together, our results identify UBE2D3 as a multi-level regulator of NHEJ that orchestrates ATM and RNF168 activities. Moreover, they reveal a negative regulatory circuit in the DDR that is constrained by UBE2D3 and consists of RNF168- and phosphatase-mediated restriction of KAP1 phosphorylation.

Indexed as

Ataxia Telangiectasia Mutated ProteinsDNA End-Joining RepairSignal TransductionTripartite Motif-Containing Protein 28Tumor Suppressor p53-Binding Protein 1UbiquitinationUbiquitin-Conjugating EnzymesUbiquitin-Protein LigasesAnimalsChromatinDNA DamageHEK293 CellsHumansPhosphorylationTelomereAtaxia Telangiectasia Mutated ProteinsATM protein, humanChromatinRNF168 protein, humanTP53BP1 protein, humanTRIM28 protein, humanTripartite Motif-Containing Protein 28Tumor Suppressor p53-Binding Protein 1UBE2D3 protein, humanUbiquitin-Conjugating EnzymesUbiquitin-Protein Ligases

Identifiers

PMID38866770
PMCPMC11169547

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.